Table 4 Base case cost effectiveness results (with 95% CIs)
Cohort Evaluated | Teriparatide vs. No Treatment | Teriparatide vs. Bisphosphonate |
|---|---|---|
PMO Patients (100% Female), age 69 years, T-Score = −3.0 | ||
historical vertebral + incident vertebral fracture | €5,897 / QALY | €19,371 / QALY |
(€5,128 – €6,612) | (€18,413 – €20,424) | |
incident vertebral fracture | €18,701 / QALY | €36,995 1 / QALY |
(€17,612 – €20,062) | (€35,252 – €38,944) | |
GIOP Patients (80% Female), age 69 years, T-Score = −2.5 | ||
historical vertebral + incident vertebral fracture | €3,271 / QALY | €15,155 / QALY |
(€2,691 – €3,853) | (€14,406 – €15,881) | |
incident vertebral fracture | € 7,330/ QALY | €20,826 / QALY |
(€6,650 – €8,062) | (€19,831 – €21,854) | |